Mechanisms of Action of Bacillus Calmette-Guérin in the Treatment of Superficial Bladder Cancer

Overview

Journal World J Urol

Specialty Urology

Date 1993 Jan 1

PMID 8401636

Citations 6

Authors

J J Patard

D K Chopin

L Boccon-Gibod

Affiliations

Soon will be listed here.

Abstract

Local immunotherapy with bacillus Calmette-Guérin (BCG) is an effective treatment to prevent recurrence and progression of superficial bladder cancer, but the antitumor mechanism of action of BCG remains unclear. There are some experimental and clinical data suggesting that BCG antigens are processed not only by immunocompetent cells but also by urothelial cells and tumor cells. The foreign antigen may be presented at the cell surface by major histocompatibility complex (MHC) class II molecules and recognized by CD4 cells. The cytotoxic effect could result from the direct activity of CD4 cells or from the cytotoxic effect of released cytokines and the activation of other cytotoxic cells [cytolytic T-lymphocytes CTLs; CD8 cells), macrophages, natural killer (NK) or lymphokine-activated killer (LAK) cells]. These mechanisms are also involved in tumor rejection, and the identification of some specific tumor rejection antigens presented to specific CTLs could provide new therapeutic approaches.

Citing Articles

Emerging intravesical therapies for the management of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer: Charting a path forward.

Chehroudi A, Black P Can Urol Assoc J. 2020; 14(6):204-213.

PMID: 31977307 PMC: 7654668. DOI: 10.5489/cuaj.6101.

Study on enhancement of fibronectin-mediated bacillus Calmette-Guérin attachment to urinary bladder wall in rabbits.

Shen Z, Wang Y, Ding G, Pan C, Zheng R World J Urol. 2007; 25(5):525-9.

PMID: 17665201 DOI: 10.1007/s00345-007-0198-z.

Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guérin (BCG) mediated antitumour activity.

Nadler R, Luo Y, Zhao W, Ritchey J, Austin J, Cohen M Clin Exp Immunol. 2003; 131(2):206-16.

PMID: 12562379 PMC: 1808633. DOI: 10.1046/j.1365-2249.2003.02071.x.

The association between CD2+ peripheral blood lymphocyte subsets and the relapse of bladder cancer in prophylactically BCG-treated patients.

Reyes E, Carballido J, Manzano L, Molto L, Olivier C, Alvarez-Mon M Br J Cancer. 1999; 79(7-8):1162-7.

PMID: 10098752 PMC: 2362230. DOI: 10.1038/sj.bjc.6690185.

Antiproliferative effects of bacillus Calmette-Guerin and interferon alpha 2b on human bladder cancer cells in vitro.

Pryor K, Stricker P, Russell P, Golovsky D, Penny R Cancer Immunol Immunother. 1995; 41(5):309-16.

PMID: 8536277 PMC: 11037707. DOI: 10.1007/BF01517219.

References

Hawkyard S, Jackson A, JAMES K, Prescott S, Smyth J, Chisholm G . The inhibitory effects of interferon gamma on the growth of bladder cancer cells. J Urol. 1992; 147(5):1399-403. DOI: 10.1016/s0022-5347(17)37582-1. View

Smith G, Ritchie A, JAMES K, Cumming J, Hargreave T, Chisholm G . Local immune responses after intravesical BCG treatment for carcinoma in situ. Br J Urol. 1987; 60(6):543-8. DOI: 10.1111/j.1464-410x.1987.tb05039.x. View

Peuchmaur M, Benoit G, Vieillefond A, Chevalier A, LEMAIGRE G, Martin E . Analysis of mucosal bladder leucocyte subpopulations in patients treated with intravesical Bacillus Calmette-Guerin. Urol Res. 1989; 17(5):299-303. DOI: 10.1007/BF00262987. View

Basham T, Merigan T . Recombinant interferon-gamma increases HLA-DR synthesis and expression. J Immunol. 1983; 130(4):1492-4. View

Boon T . Toward a genetic analysis of tumor rejection antigens. Adv Cancer Res. 1992; 58:177-210. DOI: 10.1016/s0065-230x(08)60295-x. View

De Jong W, de Boer E, van der Meijden A, Vegt P, Steerenberg P, Debruyne F . Presence of interleukin-2 in urine of superficial bladder cancer patients after intravesical treatment with bacillus Calmette-Guérin. Cancer Immunol Immunother. 1990; 31(3):182-6. PMC: 11038470. DOI: 10.1007/BF01744734. View

Buus S, Sette A, Colon S, Miles C, Grey H . The relation between major histocompatibility complex (MHC) restriction and the capacity of Ia to bind immunogenic peptides. Science. 1987; 235(4794):1353-8. DOI: 10.1126/science.2435001. View

Novick D, Engelmann H, Wallach D, Leitner O, Revel M, Rubinstein M . Purification of soluble cytokine receptors from normal human urine by ligand-affinity and immunoaffinity chromatography. J Chromatogr. 1990; 510:331-7. DOI: 10.1016/s0021-9673(01)93767-7. View

Martinez-Pineiro J, Jimenez Leon J, Fiter L, Mosteiro J, Navarro J, Garcia Matres M . Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J Urol. 1990; 143(3):502-6. DOI: 10.1016/s0022-5347(17)40002-4. View

10.

Bohle A, Gerdes J, Ulmer A, Hofstetter A, Flad H . Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol. 1990; 144(1):53-8. DOI: 10.1016/s0022-5347(17)39365-5. View

11.

Prescott S, JAMES K, Busuttil A, Hargreave T, Chisholm G, Smyth J . HLA-DR expression by high grade superficial bladder cancer treated with BCG. Br J Urol. 1989; 63(3):264-9. DOI: 10.1111/j.1464-410x.1989.tb05187.x. View

12.

Becich M, Carroll S, Ratliff T . Internalization of bacille Calmette-Guerin by bladder tumor cells. J Urol. 1991; 145(6):1316-24. DOI: 10.1016/s0022-5347(17)38622-6. View

13.

Gardiner R, Seymour G, Lavin M, Strutton G, Gemmell E, Hazan G . Immunohistochemical analysis of the human bladder. Br J Urol. 1986; 58(1):19-25. DOI: 10.1111/j.1464-410x.1986.tb05420.x. View

14.

Novick D, Engelmann H, Wallach D, Rubinstein M . Soluble cytokine receptors are present in normal human urine. J Exp Med. 1989; 170(4):1409-14. PMC: 2189483. DOI: 10.1084/jem.170.4.1409. View

15.

Ratliff T, Haaff E, Catalona W . Interleukin-2 production during intravesical bacille Calmette-Guerin therapy for bladder cancer. Clin Immunol Immunopathol. 1986; 40(2):375-9. DOI: 10.1016/0090-1229(86)90043-7. View

16.

Prescott S, JAMES K, Hargreave T, Chisholm G, Smyth J . Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J Urol. 1990; 144(5):1248-51. DOI: 10.1016/s0022-5347(17)39713-6. View

17.

Zbar B, Bernstein I, Rapp H . Suppression of tumor growth at the site of infection with living Bacillus Calmette-Guérin. J Natl Cancer Inst. 1971; 46(4):831-9. View

18.

Herr H, Laudone V, Badalament R, Oettgen H, Sogani P, Freedman B . Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer. J Clin Oncol. 1988; 6(9):1450-5. DOI: 10.1200/JCO.1988.6.9.1450. View

19.

Trinchieri G, Perussia B . Immune interferon: a pleiotropic lymphokine with multiple effects. Immunol Today. 2014; 6(4):131-6. DOI: 10.1016/0167-5699(85)90080-5. View

20.

Parnes J . Molecular biology and function of CD4 and CD8. Adv Immunol. 1989; 44:265-311. DOI: 10.1016/s0065-2776(08)60644-6. View